The application from Lykos — a drug enterprise incubated by the Multidisciplinary Association for Psychedelic Research, or MAPS — arrived with the FDA less than a cloud of controversy. Former trial individuals had alleged adverse activities weren't described — such as thoughts of suicidality after the remedy — and that bias between Those pe